Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
02/2012
02/02/2012WO2011133826A3 Method for treating pancreatic cancer
02/02/2012WO2011133480A3 Method of treating gastric cancer
02/02/2012WO2011133479A3 Combination therapy with a proteasome inhibitor and a gallium complex
02/02/2012WO2011129549A3 Anticancer drug delivery system using ph-sensitive metal nanoparticles
02/02/2012WO2011127388A3 Inverse agonists and neutral antagonists for the tsh receptor
02/02/2012WO2011127333A3 Compounds for treating disease, for administering, and for pharmaceutical compositions
02/02/2012WO2011118981A3 Novel use of erythroid differentiation regulator 1 as an agent for treating cancer
02/02/2012WO2011094335A3 Microrna signatures predicting responsiveness to anti-her2 therapy
02/02/2012WO2011091065A8 Synthetic nanostructures including nucleic acids and/or other entities
02/02/2012WO2011081465A9 Pharmaceutical composition for suppression of vascularization
02/02/2012US20120030780 Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds)
02/02/2012US20120029472 Tnfr25 agonists to enhance immune responses to vaccines
02/02/2012US20120029091 Method of controlling the release of an active ingredient from a dosage form
02/02/2012US20120029079 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids
02/02/2012US20120029070 Burdock fruit extract containing arctigenin at high content and process for producing same
02/02/2012US20120029069 Compound Extracted From Antrodia Cinnamomea and Pharmaceutical composition comprising the same
02/02/2012US20120029068 Transdermal fluid
02/02/2012US20120029067 Polyphenol Proteasome Inhibitors, Synthesis, and Methods of Use
02/02/2012US20120029063 Chimeric nk receptor and methods for treating cancer
02/02/2012US20120029062 Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof
02/02/2012US20120029055 Modulators of apoptosis and the uses thereof
02/02/2012US20120029053 Short Interfering Ribonucleic Acid (siRNA) for Oral Administration
02/02/2012US20120029052 Short Interfering Ribonucleic Acid (siRNA) for Oral Administration
02/02/2012US20120029051 siRNA Targeting VEGFA and Methods for Treatment In Vivo
02/02/2012US20120029046 Crystalline form of sunitinib and processes for its preparation
02/02/2012US20120029042 Clonidine for treatment of bone cancer
02/02/2012US20120029036 Pharmaceutical compositions comprising pyridyl cyanoguanidine, process for preparing the same and use thereof
02/02/2012US20120029026 Pyridine derivative
02/02/2012US20120029021 Nitroxide Free Radical Synergized Antineoplastic Agents
02/02/2012US20120029020 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
02/02/2012US20120029019 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
02/02/2012US20120029018 9-substituted phenanthrene based tylophorine derivatives
02/02/2012US20120029016 Indoles Useful in the Treatment of Inflammation
02/02/2012US20120029012 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF
02/02/2012US20120029007 Morphinan compounds
02/02/2012US20120029004 Novel aminopyridine derivatives having aurora a selective inhibitory action
02/02/2012US20120028997 Prokineticin 1 receptor antagonists
02/02/2012US20120028995 Novel compounds for medical use as peptidase effectors
02/02/2012US20120028994 Compounds for the reduction of beta-amyloid production
02/02/2012US20120028993 Compounds Effective Against Cancer
02/02/2012US20120028986 2-heteroaryl-pyrrolo [3,4-c]pyrrole derivatives, and use thereof as scd inhibitors
02/02/2012US20120028984 Compound Useful As A c-MET Inhibitor
02/02/2012US20120028981 Kinase Knockdown Via Electrophilically Enhanced Inhibitors
02/02/2012US20120028977 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions
02/02/2012US20120028974 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
02/02/2012US20120028966 Protein kinase inhibitors
02/02/2012US20120028965 Compounds useful as protein kinase inhibitors
02/02/2012US20120028963 Novel hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same
02/02/2012US20120028959 Dihydroorotate dehydrogenase inhibitors
02/02/2012US20120028958 5-alkynyl-pyrimidines
02/02/2012US20120028953 Azetidine Derivatives
02/02/2012US20120028952 5-alkynyl-pyrimidines
02/02/2012US20120028950 Substituted heterocyclylbenzylpyrazoles and use thereof
02/02/2012US20120028939 Substituted naphthyridines and their use as medicaments
02/02/2012US20120028927 Novel Triazene Compounds For The Treatment Of Cancer
02/02/2012US20120028925 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
02/02/2012US20120028924 Chemical compounds
02/02/2012US20120028922 Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
02/02/2012US20120028919 Pyrrolotriazines as alk and jak2 inhibitors
02/02/2012US20120028917 Use Of N-(4-((3-(2-Amino-4-Pyrimidinyl)-2-Pyridinyl)Oxy)Phenyl)-4-(4-Methyl-2-Thienyl)-1-Phthalazinamine In The Treatment Of Antimitotic Agent Resistant Cancer
02/02/2012US20120028909 FN14/TRAIL Fusion Proteins
02/02/2012US20120028908 Methods of Manufacturing Crystalline Forms of Rapamycin Analogs
02/02/2012US20120028907 Methods for identification of tumor phenotype and treatment
02/02/2012US20120028905 Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A
02/02/2012US20120028903 Modulation of the activity and differentiation of cells expressing the osteoclast-associated receptor
02/02/2012US20120028896 Use of fibroblast growth factor fragments
02/02/2012US20120028888 Apj receptor compounds
02/02/2012US20120028883 Complex and production process
02/02/2012US20120028880 Vegfr-1/nrp-1 targeting peptides
02/02/2012US20120028258 Receptor gene screening for detecting or diagnosing cancer
02/02/2012US20120027874 Compounds useful as inhibitors of atr kinase
02/02/2012US20120027873 Combination of a chemotherapeutic agent and an inhibitor of the tgf-beta system
02/02/2012US20120027870 Novel Markers for Bladder Cancer Detection
02/02/2012US20120027861 Nano-carrier, complex of anticancer drug and nano-carrier, pharmaceutical composition thereof, method for manufacturing the complex, and method for treating cancer by using the pharmaceutical composition
02/02/2012US20120027858 Methods and Compositions for Managing Cancer Cell Growth
02/02/2012US20120027850 Compositions and Methods for Treatment of Aortic Fibrosis
02/02/2012US20120027844 Compounds, their syntheses, compositions, and methods to treat cancer
02/02/2012US20120027843 Hb-egf bound protein complex
02/02/2012US20120027842 Topical formulations of flap inhibitors for administration to an eye
02/02/2012US20120027833 Drug-eluting films
02/02/2012US20120027821 Amino acid-conjugated cyanoacrylate polymer particles
02/02/2012US20120027820 Stable Formulations for Lyophilizing Therapeutic Particles
02/02/2012US20120027806 Dose selection of adjuvanted synthetic nanocarriers
02/02/2012US20120027802 Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes
02/02/2012US20120027796 Novel lipids and compositions for the delivery of therapeutics
02/02/2012US20120027794 Tuberculosis vaccine with improved efficacy
02/02/2012US20120027785 Chimera comprising bacterial cytotoxin and methods of using the same
02/02/2012US20120027784 Monomethylvaline compounds capable of conjugation to ligands
02/02/2012US20120027783 Monomethylvaline compounds capable of conjugation to ligands
02/02/2012US20120027782 Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
02/02/2012US20120027779 Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers
02/02/2012US20120027778 Frizzled-Binding Agents and Uses Thereof
02/02/2012US20120027774 Metalloproteinase 9 binding proteins
02/02/2012US20120027773 Anti-ron antibodies
02/02/2012US20120027772 Therapeutic protein formulations
02/02/2012US20120027770 Novel cell and therapeutical and diagnostical methods based thereon
02/02/2012US20120027767 Antibodies against pdgfr alpha to inhibit tumor growth
02/02/2012US20120027763 Antibody for Targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1
02/02/2012US20120027759 Methods of enhancing t cell responsiveness
02/02/2012US20120027757 Compositions and methods for treating cancer
1 ... 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 ... 2211